UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 1, 2012
RAPTOR PHARMACEUTICAL CORP.
(Exact name of registrant as specified in its charter)
| Delaware | 000-25571 | 86-0883978 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 9 Commercial Blvd., Suite 200, Novato, California 94949 | ||
(Address of principal executive offices and Zip Code) | ||
Registrant's telephone number, including area code: (415) 382-8111 | ||
| (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On November 1, 2012, Raptor Pharmaceutical Corp. (the "Company") issued a press release to report financial highlights for its fiscal year ended August 31, 2012. The Company's press release issued on November 1, 2012 is attached hereto as Exhibit 99.1. The information under the heading "Financial Highlights" are incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.
The information included in this Item 2.02 of this Current Report on Form 8-K, including the information incorporated by reference in the exhibit hereto, shall not be deemed "filed" for purposes of, nor shall it be deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
In the November 1, 2012 press release, the Company also provided an update with respect to its clinical programs, including the ongoing extension study of PROCYSBI™ (cysteamine bitartrate) delayed-release capsules for the potential treatment of patients with nephropathic cystinosis and studies on the use of RP103 for the potential treatment of Huntington's Disease and Non-Alcoholic Steatohepatitis.
The information in the Company's press release issued on November 1, 2012 as attached hereto as Exhibit 99.1, except for the information under the heading "Financial Highlights," is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Filed | |||||||
| Exhibit | Here | Incorporated by Reference | |||||
| No. | Exhibit Description | with | Form | File No. | Exhibit | Filing Date | Filed By |
| 99.1 | Press Release issued November 1, 2012. | X | |||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RAPTOR PHARMACEUTICAL CORP. | |||
Date: November 1, 2012 | By: | /s/ Christopher M. Starr, Ph.D. | |
Name: Title: | Christopher M. Starr, Ph.D. Chief Executive Officer and Director | ||
Exhibit Index
| Filed | |||||||
| Exhibit | Here | Incorporated by Reference | |||||
| No. | Exhibit Description | with | Form | File No. | Exhibit | Filing Date | Filed By |
| 99.1 | Press Release issued November 1, 2012. | X | |||||